Cyclacel Pharma (CYCC) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $309 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
- Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
- Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
